Fulcrum Therapeutics Analyst Ratings
Fulcrum Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/23/2023 | 157.83% | HC Wainwright & Co. | $5 → $14 | Upgrades | Neutral → Buy |
| 08/22/2023 | 194.66% | Oppenheimer | → $16 | Reiterates | Outperform → Outperform |
| 08/22/2023 | 102.58% | Stifel | → $11 | Upgrades | Hold → Buy |
| 08/04/2023 | -7.92% | HC Wainwright & Co. | → $5 | Reiterates | Neutral → Neutral |
| 05/16/2023 | 194.66% | Oppenheimer | $20 → $16 | Maintains | Outperform |
| 05/16/2023 | -7.92% | HC Wainwright & Co. | $6 → $5 | Maintains | Neutral |
| 05/05/2023 | -44.75% | Goldman Sachs | $9 → $3 | Maintains | Neutral |
| 05/04/2023 | -44.75% | Goldman Sachs | $9 → $3 | Downgrades | Buy → Neutral |
| 03/13/2023 | 65.75% | Goldman Sachs | $17 → $9 | Maintains | Buy |
| 03/10/2023 | 28.91% | Morgan Stanley | $8 → $7 | Maintains | Equal-Weight |
| 03/10/2023 | 10.5% | HC Wainwright & Co. | $20 → $6 | Downgrades | Buy → Neutral |
| 03/10/2023 | 47.33% | Credit Suisse | $11 → $8 | Downgrades | Outperform → Neutral |
| 02/28/2023 | 268.32% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 02/28/2023 | 47.33% | Morgan Stanley | $27 → $8 | Downgrades | Overweight → Equal-Weight |
| 02/27/2023 | 268.32% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 02/27/2023 | 268.32% | Oppenheimer | $26 → $20 | Maintains | Outperform |
| 02/27/2023 | 102.58% | Credit Suisse | $19 → $11 | Maintains | Outperform |
| 01/24/2023 | 397.24% | Morgan Stanley | $26 → $27 | Maintains | Overweight |
| 01/23/2023 | 286.74% | Piper Sandler | $18 → $21 | Maintains | Overweight |
| 01/19/2023 | 213.08% | Goldman Sachs | $11 → $17 | Maintains | Buy |
| 11/15/2022 | 102.58% | Goldman Sachs | → $11 | Initiates Coverage On | → Buy |
| 11/14/2022 | 378.82% | Morgan Stanley | $25 → $26 | Maintains | Overweight |
| 11/09/2022 | 249.91% | Credit Suisse | $22 → $19 | Maintains | Outperform |
| 06/13/2022 | 268.32% | HC Wainwright & Co. | $40 → $20 | Maintains | Buy |
| 05/17/2022 | 360.41% | Morgan Stanley | $26 → $25 | Maintains | Overweight |
| 04/12/2022 | 378.82% | Morgan Stanley | $25 → $26 | Maintains | Overweight |
| 03/25/2022 | 544.57% | Credit Suisse | $30 → $35 | Maintains | Outperform |
| 03/08/2022 | 507.73% | Oppenheimer | → $33 | Initiates Coverage On | → Outperform |
| 08/17/2021 | 636.65% | HC Wainwright & Co. | $20 → $40 | Maintains | Buy |
| 08/13/2021 | 581.4% | SVB Leerink | $23 → $37 | Maintains | Outperform |
| 08/11/2021 | 452.49% | Credit Suisse | $20 → $30 | Maintains | Outperform |
| 08/11/2021 | 526.15% | Morgan Stanley | → $34 | Upgrades | Equal-Weight → Overweight |
| 03/22/2021 | 378.82% | Credit Suisse | → $26 | Initiates Coverage On | → Outperform |
| 03/08/2021 | 120.99% | Morgan Stanley | $11 → $12 | Maintains | Equal-Weight |
| 03/02/2021 | 231.49% | Stifel | → $18 | Initiates Coverage On | → Buy |
| 11/10/2020 | 323.57% | SVB Leerink | $25 → $23 | Maintains | Outperform |
| 10/16/2020 | 305.16% | Piper Sandler | → $22 | Initiates Coverage On | → Overweight |
| 08/12/2020 | 102.58% | B of A Securities | → $11 | Downgrades | Neutral → Underperform |
| 08/12/2020 | 268.32% | HC Wainwright & Co. | $28 → $20 | Maintains | Buy |
| 08/12/2020 | 102.58% | Morgan Stanley | $29 → $11 | Downgrades | Overweight → Equal-Weight |
| 06/19/2020 | 323.57% | B of A Securities | $19 → $23 | Downgrades | Buy → Neutral |
| 06/17/2020 | 397.24% | BTIG | → $27 | Initiates Coverage On | → Buy |
| 03/06/2020 | 415.65% | HC Wainwright & Co. | $21 → $28 | Reiterates | → Buy |
| 01/23/2020 | 305.16% | B of A Securities | $19 → $22 | Maintains | Buy |
| 10/03/2019 | 286.74% | HC Wainwright & Co. | → $21 | Initiates Coverage On | → Buy |
| 08/12/2019 | 434.07% | Morgan Stanley | → $29 | Initiates Coverage On | → Overweight |
| 08/12/2019 | 249.91% | B of A Securities | → $19 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/23/2023 | 157.83% | HC Wainwright & Co. | 5 美元 → 14 美元 | 升級 | 中性 → 買入 |
| 08/22/2023 | 194.66% | 奧本海默 | → 16 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 08/22/2023 | 102.58% | Stifel | → 11 美元 | 升級 | 持有 → 買入 |
| 08/04/2023 | -7.92% | HC Wainwright & Co. | → 5 美元 | 重申 | 中性 → 中性 |
| 05/16/2023 | 194.66% | 奧本海默 | 20 美元 → 16 美元 | 維護 | 跑贏大盤 |
| 05/16/2023 | -7.92% | HC Wainwright & Co. | 6 美元 → 5 美元 | 維護 | 中立 |
| 05/05/2023 | -44.75% | 高盛 | 9 美元 → 3 美元 | 維護 | 中立 |
| 05/04/2023 | -44.75% | 高盛 | 9 美元 → 3 美元 | 降級 | 買入 → 中性 |
| 03/13/2023 | 65.75% | 高盛 | 17 美元 → 9 美元 | 維護 | 購買 |
| 03/10/2023 | 28.91% | 摩根士丹利 | 8 美元 → 7 美元 | 維護 | 重量相等 |
| 03/10/2023 | 10.5% | HC Wainwright & Co. | 20 美元 → 6 美元 | 降級 | 買入 → 中性 |
| 03/10/2023 | 47.33% | 瑞士信貸 | 11 美元 → 8 美元 | 降級 | 跑贏大盤 → 中性 |
| 02/28/2023 | 268.32% | HC Wainwright & Co. | → 20 美元 | 重申 | → 購買 |
| 02/28/2023 | 47.33% | 摩根士丹利 | 27 美元 → 8 美元 | 降級 | 超重 → 重量相等 |
| 02/27/2023 | 268.32% | HC Wainwright & Co. | → 20 美元 | 重申 | → 購買 |
| 02/27/2023 | 268.32% | 奧本海默 | 26 美元 → 20 美元 | 維護 | 跑贏大盤 |
| 02/27/2023 | 102.58% | 瑞士信貸 | 19 美元 → 11 美元 | 維護 | 跑贏大盤 |
| 01/24/2023 | 397.24% | 摩根士丹利 | 26 美元 → 27 美元 | 維護 | 超重 |
| 2023 年 1 月 23 日 | 286.74% | 派珀·桑德勒 | 18 美元 → 21 美元 | 維護 | 超重 |
| 01/19/2023 | 213.08% | 高盛 | 11 美元 → 17 美元 | 維護 | 購買 |
| 11/15/2022 | 102.58% | 高盛 | → 11 美元 | 啓動覆蓋開啓 | → 購買 |
| 11/14/2022 | 378.82% | 摩根士丹利 | 25 美元 → 26 美元 | 維護 | 超重 |
| 11/09/2022 | 249.91% | 瑞士信貸 | 22 美元 → 19 美元 | 維護 | 跑贏大盤 |
| 06/13/2022 | 268.32% | HC Wainwright & Co. | 40 美元 → 20 美元 | 維護 | 購買 |
| 05/17/2022 | 360.41% | 摩根士丹利 | 26 美元 → 25 美元 | 維護 | 超重 |
| 2022 年 12 月 4 日 | 378.82% | 摩根士丹利 | 25 美元 → 26 美元 | 維護 | 超重 |
| 03/25/2022 | 544.57% | 瑞士信貸 | 30 美元 → 35 美元 | 維護 | 跑贏大盤 |
| 03/08/2022 | 507.73% | 奧本海默 | → 33 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 2021 年 8 月 17 日 | 636.65% | HC Wainwright & Co. | 20 美元 → 40 美元 | 維護 | 購買 |
| 08/13/2021 | 581.4% | SVB Leerink | 23 美元 → 37 美元 | 維護 | 跑贏大盤 |
| 08/11/2021 | 452.49% | 瑞士信貸 | 20 美元 → 30 美元 | 維護 | 跑贏大盤 |
| 08/11/2021 | 526.15% | 摩根士丹利 | → 34 美元 | 升級 | 重量相等 → 超重 |
| 03/22/2021 | 378.82% | 瑞士信貸 | → 26 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 2021 年 8 月 3 日 | 120.99% | 摩根士丹利 | 11 美元 → 12 美元 | 維護 | 重量相等 |
| 2021 年 2 月 3 日 | 231.49% | Stifel | → 18 美元 | 啓動覆蓋開啓 | → 購買 |
| 11/10/2020 | 323.57% | SVB Leerink | 25 美元 → 23 美元 | 維護 | 跑贏大盤 |
| 2020 年 10 月 16 日 | 305.16% | 派珀·桑德勒 | → 22 美元 | 啓動覆蓋開啓 | → 超重 |
| 08/12/2020 | 102.58% | B of A 類證券 | → 11 美元 | 降級 | 中性 → 跑贏大盤 |
| 08/12/2020 | 268.32% | HC Wainwright & Co. | 28 美元 → 20 美元 | 維護 | 購買 |
| 08/12/2020 | 102.58% | 摩根士丹利 | 29 美元 → 11 美元 | 降級 | 超重 → 重量相等 |
| 2020 年 6 月 19 日 | 323.57% | B of A 類證券 | 19 美元 → 23 美元 | 降級 | 買入 → 中性 |
| 2020 年 6 月 17 日 | 397.24% | BTIG | → 27 美元 | 啓動覆蓋開啓 | → 購買 |
| 03/06/2020 | 415.65% | HC Wainwright & Co. | 21 美元 → 28 美元 | 重申 | → 購買 |
| 2020 年 1 月 23 日 | 305.16% | B of A 類證券 | 19 美元 → 22 美元 | 維護 | 購買 |
| 2019 年 3 月 10 日 | 286.74% | HC Wainwright & Co. | → 21 美元 | 啓動覆蓋開啓 | → 購買 |
| 08/12/2019 | 434.07% | 摩根士丹利 | → 29 美元 | 啓動覆蓋開啓 | → 超重 |
| 08/12/2019 | 249.91% | B of A 類證券 | → 19 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Fulcrum Therapeutics (FULC)?
Fulcrum Therapeutics（FULC）的目標價格是多少？
The latest price target for Fulcrum Therapeutics (NASDAQ: FULC) was reported by HC Wainwright & Co. on August 23, 2023. The analyst firm set a price target for $14.00 expecting FULC to rise to within 12 months (a possible 157.83% upside). 23 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年8月23日公佈了Fulcrum Therapeutics（納斯達克股票代碼：FULC）的最新目標股價。該分析公司將目標股價定爲14.00美元，預計FULC將在12個月內升至157.83％（可能上漲157.83％）。去年有23家分析公司公佈了評級。
What is the most recent analyst rating for Fulcrum Therapeutics (FULC)?
分析師對Fulcrum Therapeutics（FULC）的最新評級是多少？
The latest analyst rating for Fulcrum Therapeutics (NASDAQ: FULC) was provided by HC Wainwright & Co., and Fulcrum Therapeutics upgraded their buy rating.
HC Wainwright & Co. 提供了Fulcrum Therapeutics（納斯達克股票代碼：FULC）的最新分析師評級，Fulcrum Therapeutics上調了買入評級。
When is the next analyst rating going to be posted or updated for Fulcrum Therapeutics (FULC)?
Fulcrum Therapeutics（FULC）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fulcrum Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fulcrum Therapeutics was filed on August 23, 2023 so you should expect the next rating to be made available sometime around August 23, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與Fulcrum Therapeutics的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Fulcrum Therapeutics的最後一次評級是在2023年8月23日提交的，因此你應該預計下一個評級將在2024年8月23日左右公佈。
Is the Analyst Rating Fulcrum Therapeutics (FULC) correct?
分析師對 Fulcrum Therapeutics (FULC) 的評級是否正確？
While ratings are subjective and will change, the latest Fulcrum Therapeutics (FULC) rating was a upgraded with a price target of $5.00 to $14.00. The current price Fulcrum Therapeutics (FULC) is trading at is $5.43, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Fulcrum Therapeutics（FULC）評級已上調，目標股價爲5.00美元，至14.00美元。Fulcrum Therapeutics（FULC）目前的交易價格爲5.43美元，在分析師的預測區間內。